Clinicopathological features of squamous cell carcinoma of the lung expressing fibroblast growth factor receptor 1

doi:10.16098/j.issn.0529-1356.2015.03.011

Acta Anatomica Sinica ›› 2015 ›› Issue (3) : 354-358. DOI: 10.16098/j.issn.0529-1356.2015.03.011

MU Jing CAI Yi-ran DONG Yu-jie ZHOU Li-juan SU Dan ZHANG Hai-qing*

Author information +

History +

Abstract

Objective To investigate clinicopathological features of patients with squamous cell carcinoma of lung（SCCL) and fibroblastgrowth factor receptor 1（FGFR1）positive expression, and to explore the role of immunohistochemistry (IHC) technology in screening and confirming FGFR1 positive cases. Methods Tissue microarrays were constructed containing 208 SCCL samples. FGFR1 expression was evaluated by IHC staining to analyze its correlation with the clinicopathological characteristics. Results Among 208 patients, the frequency of FGFR1 positive expression was 6.3%. FGFR1 expression was associated with a larger tumor size (>5cm，P<0.05）, and with lymph node metastasis versus no lymph node metastasis（9.7% vs 2.9%，P<0.05）. Positive expression of FGFR1 was higher in patients with stage Ⅲ and Ⅳ than those in stage Ⅰ and Ⅱ（13.1% vs 1.6%，P<0.01）. There was no significant difference between smokers and neversmokers (P>0.05). Conclusion FGFR1 expression is associated with larger tumor size、lymph node invasion and clinical stage. FGFR1 expression is not significantly associated with clinicopathologic parameters such as age, sex, tumor location, differentiation and smoking.

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

MU Jing CAI Yi-ran DONG Yu-jie ZHOU Li-juan SU Dan ZHANG Hai-qing*. Clinicopathological features of squamous cell carcinoma of the lung expressing fibroblast growth factor receptor 1[J]. Acta Anatomica Sinica. 2015(3): 354-358 https://doi.org/10.16098/j.issn.0529-1356.2015.03.011

References

［1］Jemal A, Siegel R, Ward E, et al. Cancer statistics ［J］. CA Cancer J Clin, 2009, 59(4):225-249. 
［2］Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities［J］.Clin Cancer Res, 2012, 18(9):2443-2451.［3］Shigematsu H, Lin L, Takahashi T,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers ［J］. J Natl Cancer Inst, 2005, 97(5): 339-346. 
［4］Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer［J］. N Engl J Med, 2010, 363(18):1693-1703.
［5］Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer［J］. PLoS One, 2011, 6(6):e20351.
［6］Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cance［J］. Sci Transl Med, 2010, 2(62):62ra93.
［7］Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study［J］. Lancet Oncol, 2012, 13(1): 33-42.
［8］Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours［J］. J Thorac Oncol, 2007, 2(8): 706-714.
［9］Sugiura K, Ozawa S, Kitagawa Y, et al. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma［J］. Oncol Rep, 2007,17(3): 557-564.
［10］Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes［J］. Cancer Cell, 2006,10(6):515-527.
［11］Kuroso K, Imai Y, Kobayashi M, et al. Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis［J］. Pathobiology, 2010, 77(5): 231-240.
［12］Nord H, Segersten U, Sandgren J,et al. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma［J］. Int J Cancer,2010,126(6):1390-1402.
［13］Naimi B, Latil A, Fournier G, et al. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate［J］. Prostate, 2002,52(3):245-252.
［14］Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer［J］. Br J Cancer,2005, 92(2):320-327.
［15］Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung［J］. J Thoracic Oncol, 2012, 7(12): 1775-1780.
［16］Kohler LH, Mireskandari M, Knsel T, et al. FGFR1 expression and gene copy numbers in human lung cancer［J］. Virchows Arch, 2012, 461(1): 49-57.
［17］Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient derived tumor xenograft PDTX models［J］. Clin Cancer Res, 2012,18(24): 6658-6667.
［18］Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer［J］. J Clin Oncol, 2013, 31(6): 731-737.